Literature DB >> 17635080

Associations of blood levels of insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-3 in schizophrenic Arab subjects.

Abayomi O Akanji1, Jude U Ohaeri, Suhail A Al-Shammri, Hasmukh R Fatania.   

Abstract

BACKGROUND: Insulin-like growth factors (IGFs) are believed to be important in brain development and repair following neuronal damage. It is also speculated that IGFs are involved in the association of foetal and pre-adult growth with schizophrenia (SZ).
METHODS: The aim of this study was to assess levels of IGF-I, IGF-II and IGF binding protein (IGFBP)-3 and their associations in male Arab patients with SZ (n=53) and healthy control subjects (HC; n=52). Anthropometric and demographic data were collected for each subject for whom blood specimens were analysed for serum lipoproteins, apolipoprotein B (apoB), IGF-I, IGF-II and IGFBP-3.
RESULTS: The SZ group had lower serum total cholesterol, apoB and uric acid levels than the HC group (p<0.05). IGF-II levels were significantly higher in the SZ group (p=0.02) and correlated positively with levels of atherogenic lipoproteins--total cholesterol, low-density lipoprotein, apoB--and IGFBP-3. The pattern of correlations between the IGFs and the various parameters differed somewhat between the HC and SZ groups.
CONCLUSIONS: These results demonstrate that IGF-II levels are increased in patients with SZ and show significant associations with atherogenic lipoproteins. We suggest a possible link between IGF-II metabolism and atherogenesis in SZ.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635080     DOI: 10.1515/CCLM.2007.265

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

1.  Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model.

Authors:  Viviane Labrie; Ryutaro Fukumura; Anjali Rastogi; Laura J Fick; Wei Wang; Paul C Boutros; James L Kennedy; Mawahib O Semeralul; Frankie H Lee; Glen B Baker; Denise D Belsham; Steven W Barger; Yoichi Gondo; Albert H C Wong; John C Roder
Journal:  Hum Mol Genet       Date:  2009-05-30       Impact factor: 6.150

2.  Assessment Causality in Associations Between Serum Uric Acid and Risk of Schizophrenia: A Two-Sample Bidirectional Mendelian Randomization Study.

Authors:  Qianqian Luo; Zheng Wen; Yuanfan Li; Zefeng Chen; Xinyang Long; Yulan Bai; Shengzhu Huang; Yunkun Yan; Rui Lin; Zengnan Mo
Journal:  Clin Epidemiol       Date:  2020-02-26       Impact factor: 4.790

Review 3.  Insulin-Like Growth Factor 2 As a Possible Neuroprotective Agent and Memory Enhancer-Its Comparative Expression, Processing and Signaling in Mammalian CNS.

Authors:  Alexander Beletskiy; Ekaterina Chesnokova; Natalia Bal
Journal:  Int J Mol Sci       Date:  2021-02-12       Impact factor: 5.923

4.  Uric Acid Potential Role in Systemic Inflammation and Negative Symptoms After Acute Antipsychotic Treatment in Schizophrenia.

Authors:  Milica M Borovcanin; Slavica Minic Janicijevic; Natasa R Mijailovic; Ivan P Jovanovic; Nebojsa N Arsenijevic; Katarina Vesic
Journal:  Front Psychiatry       Date:  2022-02-14       Impact factor: 4.157

5.  Insulin-like Growth Factor 2 (IGF-2) and Insulin-like Growth Factor Binding Protein 7 (IGFBP-7) Are Upregulated after Atypical Antipsychotics in Spanish Schizophrenia Patients.

Authors:  Carlos Fernández-Pereira; Maria Aránzazu Penedo; Tania Rivera-Baltanas; Rafael Fernández-Martínez; Saida Ortolano; José Manuel Olivares; Roberto Carlos Agís-Balboa
Journal:  Int J Mol Sci       Date:  2022-08-24       Impact factor: 6.208

6.  Decreased IL-1ra and NCAM-1/CD56 Serum Levels in Unmedicated Patients with Schizophrenia Before and After Antipsychotic Treatment.

Authors:  Che-Sheng Chu; Dian-Jeng Li; Chin-Liang Chu; Chih-Ching Wu; Ti Lu
Journal:  Psychiatry Investig       Date:  2018-06-15       Impact factor: 2.505

7.  Altered insulin-like growth factor-2 signaling is associated with psychopathology and cognitive deficits in patients with schizophrenia.

Authors:  Yuan-Jian Yang; Tao Luo; Ying Zhao; Shu-Zhen Jiang; Jian-Wen Xiong; Jin-Qiong Zhan; Bin Yu; Kun Yan; Bo Wei
Journal:  PLoS One       Date:  2020-03-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.